Long Term Efficacy and Safety of Eryfotona AK-NMSC® in Patients With Actinic Keratosis

Inclusion Criteria: 1. Current diagnosis of AK, with ≥4 lesions located in the same anatomical district (within a contiguous 50 cm2 area on the face, bold scalp or forehead); 2. Female or male \>18 years of age; 3. Skin type I or II according to Fitzpatrick; 4. Patient has confirmed his/her willingness to participate in this study;. Exclusion Criteria: 1. Topical drug therapy for AK within the past 3 months or for photoaging in the last 6 months, or had lesion-directed therapy within 2 cm2 of the selected AK area during the previous month; 2. Suitable for surgical, photodynamic or any other topical treatment in the next 6 months; 3. Subjects who suffer/ had suffered from skin cancer or show an early stage of skin cancer or have a genetic predisposition for skin cancer; 4. Other skin disease that requires treatment with other medications in the treatment area or in the distance of 3 cm; 5. Immunosuppression or current treatment for cancer; 6. Clinically unstable medical condition; 7. High risk group for HIV infection or presentation of other infectious diseases 8. Presentation of contact allergies or allergies to compounds of the test substances; 9. Smoker (more than forty cigarettes per day) or heavy drinker (more than three standard drinks per day); 10. Psychiatric disease that may interfere with follow up of study procedures; 11. Participation in other clinical trials up to 30 days prior to day 1 of the study 12. Prior treatment with study medication in the area to be treated; 13. Considered by the investigator, for any other reason, to be an unsuitable candidate for the study.